CHMCHIMERIC THERAPEUTICS LIMITEDMarket sensitive

CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi

Date and time
Announcement type
Company Update
Show details
Category
Other
Report codes
11001
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
View on ASXOpen original PDFCHM announcement history

Recent CHM announcements